Lipidomic analysis of plasma lipids composition changes in septic mice

Won-Gyun Ahn*, Jun-Sub Jung#, and Dong-Keun Song*

Department of Pharmacology, College of Medicine, Institute of Natural Medicine, Hallym University, Chuncheon 24252, Korea

ABSTRACT A lipidomic study on extensive plasma lipids in bacterial peritonitis (cecal ligation and puncture, CLP)-induced sepsis in mice was done at 24 h post-CLP. The effects of administration of lysophosphatidylcholine (LPC) and lysophosphatidic acid (LPA), compounds known to have beneficial effects in CLP, on the sepsis-induced plasma lipid changes were also examined. Among the 147 plasma lipid species from 13 lipid subgroups (fatty acid [FA], LPA, LPC, lysophosphatidylethanolamine [LPE], phosphatidic acid [PA], phosphatidylethanolamine [PC], phosphatidylglycerol [PG], monoacylglycerol [MG], diacylglycerol [DG], triacylglycerol [TG], sphingomyelin [SM], and ceramide [Cer]) analyzed in this study, 40 and 70 species were increased, and decreased, respectively, in the CLP mice. Treatments with LPC and LPA affected 14 species from 7 subgroups, and 25 species from 9 subgroups, respectively. These results could contribute to finding the much needed reliable biomarkers of sepsis.

INTRODUCTION

Biofluid lipidome is recently regarded as a source for potential diagnostic biomarkers [1]. Particularly, lipidomics showed a remarkable diversity of lipids in plasma [2]. Septic patients [3-11] and experimental animals [12] have shown changes in some of the plasma lipids. However, a lipidomic study on extensive plasma lipids in sepsis has not yet been done. Cecal ligation and puncture (CLP) induces the polymicrobial peritonitis, and is regarded as a reliable animal model of sepsis [13]. Thus, in the present study, we examined changes of 147 plasma lipid species from 13 subgroups of lipids, i.e. fatty acid (FA), lysophosphatidic acid (LPA), lysophosphatidylcholine (LPC), lysophosphatidylethanolamine (LPE), phosphatidic acid (PA), phosphatidylcholine (PC), phosphatidylglycerol (PG), monoacylglycerol (MG), diacylglycerol (DG), triacylglycerol (TG), sphingomyelin (SM), and ceramide (Cer) in CLP-induced murine sepsis.

We previously reported the therapeutic effects of LPC administration in experimental sepsis [14] and the CLP-induced alteration of LPC-related metabolic parameters in the plasma [15]. Although LPC administration in experimental sepsis was found to decrease inflammatory cytokines and to enhance bacterial clearance [14], we hypothesized that LPC administration may also affect plasma lipid changes in CLP mice. Thus, the effects of LPC and its precursor, LPA having similar beneficial actions against sepsis (unpublished observation), on the sepsis-induced plasma lipid changes were also examined.

Among the 147 plasma lipid species analyzed in this study, levels of 110 species were changed in the CLP; 40 species were increased, and 70 species were decreased. LPC and LPA treatment affected 14 lipid species of 7 subgroups, and 25 lipid species of 9 subgroups, respectively.

Key Words
- Lipidomics
- Mice
- Plasma
- Sepsis

*These authors contributed equally to this work.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright © Korean J Physiol Pharmacol, pISSN 1226-4512, eISSN 2093-3827
METHODS

Animals

Male ICR mice at the age of 5 weeks (26–28 g body weight) were used. The procedures for animal experiments were approved by the Animal Experimentation Committee at Hallym University.

CLP operation, and LPC or LPA injection

CLP was performed as described previously [13,14]. Briefly, after pentobarbital anesthesia, two through-and-through punctures with a 21-G needle were made at the ligated cecum. For sham operation, punctures were omitted. At 24 h after CLP or sham operation, 100 μl of plasma was prepared from blood obtained from retro-orbital plexus. No lethality was observed up to 24 h post-CLP. 18:0 LPC or 18:0 LPA (10 mg/kg, Avanti Polar Lipids, Alabaster, AL) was administered subcutaneously at 2 h and 14 h post-CLP.

Lipid metabolite analysis

Plasma samples were thawed to room temperature, and extraction was performed using chloroform:methanol mixture (2:1, v/v) as modified by Folch et al. [16]. Serum lipid extracts were diluted with isopropanol:acetonitrile:water mixture (2:1:1, v/v/v), and injection was used for UPLC/Q-TOF MS. LC-MS was performed on a quadruple time-of-flight MS/MS system (impact HD UHR-QTOF system, Bruker Daltonick, Bremen, Germany) combined with a UPLC system (Waters, Milford, MA). Separations were performed on an Acquity UPLC BEH C18 column (2.1×100 mm with 1.7-μm particles; Waters). The binary gradient system comprised 10 mM ammonium acetate in acetonitrile:water (4:6, v/v) and 10 mM ammonium acetate in acetonitrile/isopropanol (1:9, v/v). The flow rate was maintained at 0.35 ml/min for 20 min. The mass spectrometer was operated in the electrospray ionization-positive and -negative modes, and the mass range was set at m/z 100-1500.

All MS data, including retention times, m/z, and ion intensities, were extracted by the Progenesis QI software (Waters, Milford, MA) incorporated within the instrument, and the resulting data were assembled into a matrix. Ion intensity was normalized with the internal standard using 1-(10Z-heptadecenoyl)-sn-glycero-3-phosphocholine, 1-heptadecanoyl-2-(9Z-tetradecenoyl)-sn-glycero-3-phosphocholine, and 1,3(d5)-diheptadecanoyl-2-(10Z-heptadecenoyl)-glycerol. The means of duplicate samples and <20% RSD of QC were utilized in the statistical analysis. Metabolites were identified using the LipidMap (www.lipidmaps.org) and Human Metabolome databases (www.hmdb.ca) and confirmed using standard samples (Avanti Polar Lipids) based on retention

Fig. 1. UPLC/Q-TOF MS spectra of serum lipid extracts in positive and negative mode. The base peak intensity (BPI) chromatograms obtained from an analysis in positive (A) and negative (B) ionization mode are shown. LC-MS was performed on a quadruple time-of-flight MS/MS system combined with a UPLC system.
Statistical analysis

Statistical analysis was performed with Statistical Package for the Social Sciences software, version 15.0 (SPSS Inc., Chicago, IL). The Mann–Whitney U-test (non-parametric t-test) and the Wilcoxon rank-sum test were conducted for the between-group comparisons, and p-value <0.05 was considered to be statistically significant. A multivariate statistical analysis to pattern analysis was performed using SIMCA-P+ software, version 12.0 (Umetrics, Umeå, Sweden). Cross-validation with seven cross-validation groups was used throughout the analysis to determine the number of principal components. A partial least-squares discriminant analysis (PLS-DA) was used as classification methods to model the discrimination by visualizing the score plot.

RESULTS

Pattern analysis and identification of lipid metabolites

The base peak intensity (BPI) chromatograms obtained from an analysis in positive and negative ionization mode are present-
ed in Fig. 1. We obtained a total of 3591 and 1725 aligned spectral features in UPLC/Q-TOF positive and negative modes, respectively. In global lipidomic profiling, the PLS-DA model showed a clear separation between the CLP and sham mice in both the positive (R²=0.996, Q²=0.963) (Fig. 2A) and negative ionization mode (R²=0.991, Q²=0.951) (Fig. 2C). The permutation test with a permutation number of 100 was performed and indicated R² intercept value of 0.796 and 0.639 and Q² intercept value of 0.053 and –0.146 in positive and negative mode, respectively (Figs. 2B and D).

We annotated 147 lipid metabolites from 13 lipid classes including FA, LPC, LPE, LPA, PC, PE, PI, PA, MG, DG, TG, SM, and Cer in the positive and negative ionization mode. In targeted lipidomic profiling, the PLS-DA model showed a clear separation between the CLP and sham mice (R²=0.989, Q²=0.970) (Fig. 2E) and a permutation plot showed high predictability values (R² intercept=0.417, Q² intercept=–0.247) (Fig. 2F).

**CLP-induced changes in plasma lipid metabolites**

To investigate the significant differences according to lipid classes and acyl chain components of lipid species, we performed the statistical analysis (p<0.05 and variable importance of projection [VIP] of >1). Among lipid classes, sphingolipids (SM and Cer)
and glycerolipids (MG, DG, and TG) showed remarkable difference between sham and CLP mice (Fig. 3). The species of SM and Cer had significantly higher levels in CLP mice than sham mice, and particularly SM d36:1 and d38:1 had remarkably high levels in CLP mice (>400%). The species of MG, DG, and TG showed significantly lower levels in CLP mice than sham mice, except DG containing carbon number 38 and double bond number 4 and 5 and TG containing carbon number 56 and 58 and double bond number more than 6 (TG 56:7, 56:8, 58:8, 58:9, and 58:10).

In addition, we compared compositions of FA, PC, and TG according to carbon number of acyl chain (Fig. 4). Sham and CLP mice showed different composition by containing carbon number of acyl chain; the CLP group showed higher composition of long chain acyl component compared with sham mice.

**Effect of LPC or LPA on lipid metabolites in CLP**

To investigate the effect of LPC or LPA on lipid metabolites in CLP, we performed the pattern analysis using the PLS-DA model and Mann–Whitney U-test. In pattern analysis based on target analysis data, the sham group and CLP groups (CLP, CLP+LPC, and CLP+LPA) were clearly classified (Fig. 5A). Furthermore, the difference pattern was observed between CLP and LPC/LPA treatment groups (CLP+LPC, and CLP+LPA) (Fig. 5B). The difference patterns between each lysophospholipid (LPC or LPA) were also observed (Figs. 5C and D).

The LPC or LPA treatment groups showed common alteration of LPA 20:0 and 22:0, LPC 18:0, 18:2, 20:2, 22:1, and 22:5, PC 30:0, 30:1, and 36:0 and PE 34:1 (Fig. 6A). The levels of LPA 20:0 and 22:0, LPC 18:0, 18:2, 20:2, 22:1, and 22:5, and PC 36:0 were significantly increased in LPC or LPA treatment groups when compared with the non-treatment group (CLP group), whereas the levels

---

**Fig. 4.** Compositions of (A) fatty acid (FA), (B) phosphatidylcholine (PC), and (C) triacylglyceride (TG) according to the carbon number of acyl chain in the sham and CLP mice. At 24 h after sham or CLP operation, plasma was prepared from blood obtained from retro-orbital plexus. FA, PC, and TG were measured as described in Methods.

---
of PC 30:0 and 30:1 and PE 34:1 were significantly decreased in LPC or LPA treatment groups. The elevated levels of FA 20:0 and the reduced levels of FA 14:0 and TG 48:1 and 48:2 were shown in LPC-treated group, but not in LPA-treated one (Fig. 6B). On the contrary, the elevated levels of FA 18:0, LPC 20:3, 20:4, 22:0, and 22:6, LPE 20:0, PC 34:0, 38:4, and 40:5, PE 34:0, MG 16:0 and 18:0, DG 36:0, and SM d34:1 and the reduced levels of LPE 18:1, PC 32:2 and 34:1, and PI 38:5 were shown only in the LPA-treated group (Fig. 6C).

Significant changes of glycerolipids by CLP

Among significant changes of lipid metabolites by sepsis with or without LPA/LPC treatment, changes of glycerolipids including MG, DG, and TG were most prominent (Fig. 7). The glycerolipids levels were dramatically reduced about 90% in CLP group compared with sham group. By the LPA treatment in CLP mice, the species of MG and DG showed significantly increased levels; particularly, the levels of MG 16:0 and 18:0 and DG 36:0 were elevated by 94%, 171%, and 47% compared with CLP group, respectively. By the LPC treatment in CLP mice, the species of TG showed significantly decreased levels; particularly, the levels of TG 48:1 and 48:2 were decreased by 88% and 80% compared with CLP group, respectively.

Phospholipids (PA, PC, PE, and PI) showed diverse changes in CLP; PAs and PEs mostly increased, while PCs either increased or decreased depending on the PC species, and all the PIs decreased (Fig. 8). Lysophospholipids (LPA, LPC, and LPE) also revealed diverse changes in CLP; LPAs showed varied changes, while LPCs and LPEs more likely decreased in CLP (Fig. 8). FAs mostly increased (Fig. 8).

DISCUSSION

In sepsis patients, alterations in the levels of various plasma lipids has been reported [3-11]. In the present study, all the 13 lipid subgroups showed significant changes at least in some individual lipid species at day 1 in CLP. Our study of plasma lipid changes in murine sepsis is largely compatible with those in human septic patients, while some findings are inconsistent.

Levels of plasma LPCs have been repeatedly observed to be decreased in sepsis patients [3,8,10]. In sepsis patients at day 1, levels of plasma LPC 16:0, 18:0, 18:1, 18:2 were shown to be markedly reduced [3]. In a similar vein, decrease in plasma LPC 16:1 at day 1 was also reported in non-survivors compared with survivors in
Sepsis-induced changes in plasma lipids

In the present study, plasma levels of LPC 16:0 and 18:0 were not changed, while plasma levels of LPC 18:1 and 18:2 were reduced (21-33%) (Fig. 8). One possible mechanism for the decrease in plasma LPC levels in septic patients was suggested to be the enhanced conversion to LPA [3]. Recently, we reported that LPC-related metabolic parameters in plasma (i.e., PC, LPA, secretory phospholipase A2, lecithin:cholesterol acyltransferase, acyl-CoA:lysophosphatidylcholine acyltransferase, and autotaxin, and albumin) in CLP mice are altered, suggesting the contribution of all those parameters to the decrease in plasma LPC in CLP mice [15]. In that study, plasma levels of both total PC and total LPA were increased, suggesting that conversion from PC to LPC is decreased, whereas that from LPC to LPA is increased [15]. However, in the present study where we measured each species of PC, LPC and LPA, the co-relationship among those three phospholipids was not so evident due to the variance among the species of the lipids (Fig. 8).

Decrease in LPEs 18:1, 18:2, and 20:4 was observed in CLP (Fig. 8). Interestingly, decrease in LPE 20:4 in non-survived vs survived septic patients was noted [9].

Recently, a lipidomic study in septic patients showed a significant increase in plasma PCs 32:0, 34:1, 34:2, 36:1 [6]. We similarly observed a modestly significant increase (12-32%) in plasma PCs 32:0, 34:1, 34:2, 38:4, and 38:6 in CLP mice, while changes in PC 36:1 were not significant (Fig. 8). Decrease in plasma PC 38:4, 38:6 at day 1 was reported in non-survivors compared with survivors in sepsis patients [10]. Thus, increase in plasma PC 38:4, 38:6 at day 1 in CLP could be beneficial for survival in sepsis.

In sepsis patients at day 1, levels of plasma Cer 23:0, 24:0 were shown to be markedly reduced, while Cer 16:0, 18:0, 20:0, 22:1, and 24:1 significantly increased [3]. The increase in plasma Cer in sepsis was ascribed to the increase in the serum levels of secretary

---

**Fig. 6.** Significant changes in lipid metabolites induced by LPC or LPA treatment. 18:0 LPC or 18:0 LPA was administered subcutaneously at 2 h and 14 h post-CLP at the dose of 10 mg/kg. At 24 h after sham or CLP operation, plasma was prepared from blood obtained from retro-orbital plexus. Significant changes common to LPC or LPA treatment (A), significant changes observed only in LPC treatment (B), and significant changes observed only in LPA treatment (C).
sphingomyelinase activity in the systemic inflammation [3,17]. In the present study, plasma levels of Cer 24:1 (d42:2, d18:1/24:1) and SM d40:1 (d18:0/22:1(OH)) were markedly increased (Fig. 3). A recent lipidomic study in septic patients showed a significant increase in plasma SM d40:1, d40:2 [6]. S Ms consistently increased in CLP, the increases in SM 36:1 and 38:1 being most prominent, more than 500% increase (Fig. 3). These findings illustrate the similarity in sepsis-induced plasma lipid changes between humans and mice.

The increase in plasma FAs in sepsis was observed both in experimental septic animals and septic patients [5,11]. It was partly ascribed to the increased liberation of FAs from adipose tissue induced by the rise in plasma catecholamines in sepsis [5]. Previously, serum FAs levels from 12 h post-CLP rats were shown to be either decreased (FAs 18:0, 18:1, and 18:2) or increased (FAs 18:3, 22:5, and 22:6) especially in non-survivors [12]. Largely in a similar vein, plasma FA levels from 24 h post-CLP mice were also shown to be either decreased (FAs 18:0, 20:0, and 20:5) or increased (FAs 14:1, 18:1, 18:2, 20:2, 20:4, 22:4, and 22:6) (Fig. 8). A slight discrepancy between each study could be resulted from the differences in the sampling time, species, or severity of sepsis.

Lipopolysaccharide was reported to increase intracellular levels of PA [18]. However, the changes in plasma levels of PA in sepsis has not been reported. We observed more than 300% increase in PA 36:2 in plasma in CLP (Fig. 8). We also firstly observed a consistent decrease in the plasma levels of all the PIs in CLP.

Plasma TG was reported to be increased at day 1 of septic patients [11]. However, the decrease in plasma TG was found in this study (Fig. 5). It is to be noted that as one of the principal early symptoms of CLP at 24 h post-CLP is a profound decrease in food intake, at least part of the changes in the plasma lipids observed in CLP in this study could be resulted from the fasting effect. Plasma lipid profile in the 24 h-fasted mice shows a decrease in TGs and FAs, with no change in phospholipids [19]. Thus, a substantial portion of the decrease in TGs (Figs. 3 and 7) and possibly parts of the decrease in MGs and DGs (Figs. 3 and 7) could be due to CLP-induced decrease in food intake.

Both LPC and LPA treatment affected a wide range of lipid species quite similarly (Fig. 6). However, the influence exerted by LPA treatment on the plasma lipid levels was more profound than that by LPC treatment, suggesting that LPA either directly or indirectly affects a wider range of lipids than LPC. Furthermore, a possibility is raised that at least part of the antiseptic effects of LPC [14] is mediated by LPA. However, it is uncertain whether the changes in plasma lipids induced by LPA or LPC treatment, at least in part, contribute to the beneficial effects of these lysophospholipids against CLP-induced sepsis [14].

Collectively, the extensive plasma lipidomics study in the CLP

![Fig. 7. Marked changes in glycerolipids induced by CLP and LPC/LPA treatment.](Image)
Sepsis-induced changes in plasma lipids

Korean J Physiol Pharmacol 2018;22(4):399-408

www.kjpp.net

Sepsis-induced changes in plasma lipids

led to the observation that the levels of a vast range of plasma lipids are altered. Apart from confirming previously reported findings in sepsis, we newly found the alteration of some lipids in the plasma in CLP mice, i.e. PA, and PI. The specific mechanisms for CLP-induced changes in the levels of each plasma lipid observed in this study remain to be fully clarified. The findings of the present study could be useful for the development of reliable biomarkers of sepsis which are much needed for early diagnosis and prediction of prognosis [20-23].

ACKNOWLEDGEMENTS

Lipidomic analysis by Dr. Ju Yeon Park and Won Gyo Jang under the supervision of Prof. Geum-Sook Hwang, Integrated Metabolomics Research Group, Western Seoul Center, Korea Basic Science Institute is greatly appreciated. This work was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF-2015R1D1A1A01059728, NRF-2017R1D1A1B03035569) and Hallym University Research Fund (HRF-201701-015).

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

Fig. 8. Changes in plasma phospholipids, lysophospholipids and FA levels at 24 h post-CLP. At 24 h after sham or CLP operation, plasma was prepared from blood obtained from retro-orbital plexus. (A-H) Phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidic acid (PA), lysophosphatidylcholine (LPC), lysophosphatidylethanolamine (LPE), lysophosphatidic acid (LPA), phosphatidylinositol (PI), and fatty acid (FA) were measured as described in Methods.
REFERENCES

1. Ghosh A, Nishtala K. Biofluid lipidome: a source for potential diagnostic biomarkers. Clin Transl Med. 2017;6:22.

2. Quehenberger O, Armando AM, Brown AH, Milne SB, Myers DS, Merrill AH, Bandypadhyay S, Jones KN, Kelly S, Shaner RL, Sul lards CM, Wang E, Murphy RC, Barkley RM, Leiker TJ, Raetz CR, Guan Z, Laird GM, Six DA, Russell DW, McDonald JG, Subramani am S, Fahy E, Dennis EA. Lipidomics reveals a remarkable diversity of lipids in human plasma. J Lipid Res. 2010;51:3299-3305.

3. Drobnik W, Liebsch G, Audebert FX, Frohlich D, Gluck T, Vogel P, Rothe G, Schmitz G. Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patients. J Lipid Res. 2003;44:754-761.

4. Levels JH, Pajkrt D, Schultz M, Hoek FJ, van Tol A, Meijers JC, van Deventer SJ. Alterations in lipoprotein homeostasis during human experimental endotoxemia and clinical sepsis. Biochim Biophys Acta. 2007;1771:1429-1438.

5. Nogueira AC, Kawabata V, Biselli P, Lins MH, Valeri C, Seckler M, Hoshino W, Junior LG, Bernik MM, de Andrade Machado JB, Martinez MB, Lotufo PA, Caldini EG, Martins E, Curi R, Soriano FG. Changes in plasma free fatty acid levels in septic patients are associated with cardiac damage and reduction in heart rate variability. Shock. 2008;29:342-348.

6. Schmerler D, Neugebauer S, Ludewig K, Bremer-Streck S, Brunkhorst FM, Kiehnthopf M. Targeted metabolomics for discrimination of systemic inflammatory disorders in critically ill patients. J Lipid Res. 2012;53:1369-1375.

7. Rival T, Cinq-Frais C, Silva-Sifontes S, Garcia J, Riu B, Salvayre R, Genestal M, Caspar-Bauguil S. Alteration of plasma phospholipid fatty acid profile in patients with septic shock. Biochimie. 2013;95:2177-2181.

8. Park DW, Kwak DS, Park YY, Chang Y, Huh JW, Lim CM, Koh Y, Song DK, Hong SB. Impact of serial measurements of lysophosphatidylcholine on 28-day mortality prediction in patients admitted to the intensive care unit with severe sepsis or septic shock. J Crit Care. 2014;29:882.e5-882.e11.

9. Rogers AJ, McGeachie M, Baron RM, Gazourian L, Haspel JA, Nakahira K, Frederburgh LE, Hunninghake GM, Raby BA, Mat thay MA, Otero RM, Fowler VG, Rivers EP, Woods CW, Kingsmore S, Langley RJ, Choi AM. Metabolomic derangements are associated with mortality in critically ill adult patients. PLoS One. 2014;9:e87538.

10. Ferrario M, Cambiaghi A, Brunelli L, Giordano S, Caironi P, Guatteri L, Raimondi F, Gattinoni L, Latini R, Masson S, Ristagno G, Pastorelli R. Mortality prediction in patients with severe septic shock: a pilot study using a target metabolomics approach. Sci Rep. 2016;6:20391.

11. Bermudes ACG, de Carvalho WB, Zamberlan P, Muramoto G, Maranhão RC, Delgado AF. Changes in lipid metabolism in pediatric patients with severe sepsis and septic shock. Nutrition. 2018;47:104-109.

12. Xu PB, Lin ZY, Meng HB, Yan SK, Yang Y, Liu XR, Li JB, Deng XM, Zhang WD. A metabonomic approach to early prognostic evaluation of experimental sepsis. J Infect. 2008;56:474-481.

13. Rittirsch D, Huber-Lang MS, Flierl MA, Ward PA. Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protoc. 2009;4:31-36.

14. Yan JJ, Jung JS, Lee JE, Lee J, Huh SO, Kim HS, Jung KC, Cho JY, Nam JS, Suh HW, Kim YH, Song DK. Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat Med. 2004;10:161-167.

15. Ahn WG, Jung JS, Kwon HY, Song DK. Alteration of lysophosphatidylcholine-related metabolic parameters in the plasma of mice with experimental sepsis. Inflammation. 2017;40:537-545.

16. Folch J, Lees M, Sloane-Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957;226:497-502.

17. Wong ML, Xie B, Beattini N, Phu P, Marathe S, Johns A, Gold PW, Hirsch E, Williams KJ, Licinio J, Tabas I. Acute systemic inflammation up-regulates secretory sphingomyelinase in vivo: a possible link between inflammatory cytokines and atherogenesis. Proc Natl Acad Sci U S A. 2000;97:8681-8686.

18. Rice GC, Brown PA, Nelson RJ, Bianco JA, Singer JW, Bursten S. Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid. Proc Natl Acad Sci U S A. 1994;91:3857-3861.

19. Sokolović M, Sokolović A, van Roomen CP, Gruber A, Ottenhoff R, Scheij S, Hakvoort TB, Lamers WH, Groen AK. Unexpected effects of fasting on murine lipid homeostasis−transcriptomic and lipid profiling. J Hepatol. 2010;52:737-744.

20. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010;14:R15.

21. Reinhart K, Bauer M, Riedemann NC, Hartog CS. New approaches to sepsis: molecular diagnostics and biomarkers. Clin Microbiol Rev. 2012;25:609-634.

22. Cho SY, Choi JH. Biomarkers of sepsis. Infect Chemother. 2014;46:1-12.

23. Bloos F, Reinhart K. Rapid diagnosis of sepsis. Virulence. 2014;5:154-160.